Columbus OH 镰状细胞病临床试验
9项针对 镰状细胞病的研究正在 Columbus及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
HPC Offered for PRESERVE Expansion
招募中观察性研究
- The Ohio State University Medical Center, Columbus
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
招募中2 期
- Ohio State University, Columbus
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
招募中2 期
- The Ohio State University, Columbus
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
招募中3 期
- Ohio State Univ Wexner Med Ctr, Columbus
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
招募中观察性研究
- Ohio State University Medical Center, Columbus
- Nationwide Children's Hospital Columbus, Columbus
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
招募中1/2 期
- Nationwide Children's Hospital, Columbus
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
招募中观察性研究
- Nationwide Children's Hospital (NT-DMT), Columbus
Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
招募中
- The Ohio State University Medical Center, Columbus
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
招募中2 期
- Nationwide Children's Hospital, Columbus
其他城市的 镰状细胞病试验
- Washington, DC21 项研究
- Atlanta, GA20 项研究
- Memphis, TN19 项研究
- Chicago, IL18 项研究
- New York City, NY16 项研究
- Philadelphia, PA15 项研究
- Birmingham, AL14 项研究
- Houston, TX12 项研究
- Boston, MA12 项研究
- St. Louis, MO12 项研究
- Durham, NC10 项研究
- Cincinnati, OH10 项研究
Columbus的其他研究
- 非小细胞肺癌57 项研究
- 癌症(所有类型)40 项研究
- 乳腺癌39 项研究
- 卵巢癌39 项研究
- 肺癌36 项研究
- 急性髓系白血病34 项研究
- 慢性淋巴细胞白血病29 项研究
- 转移性癌症25 项研究
- 多发性骨髓瘤25 项研究
- 前列腺癌25 项研究
- 子宫内膜癌24 项研究
- 结直肠癌24 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年11月15日。每项研究自行设定入选标准,由研究团队决定谁能参与。